Zithrax (Azithromycin) IV
“Once Daily & Tissue Directed Action”
SZithrax infusion is a novel molecule belongs to the macrolides class of antibiotics. It contains Azithromycin dehydrate as active ingredient and is one of the advanced therapeutic options amongst macrolides. ZITHRAX (Azithromycin) provides quick and fast recovery to patients with the convenience of OD dosage. Strong pharmacokinetics and pharmacodynamic of Zithrax (IV Azithromycin) make this brand powerful, simple, tissue directed and novel. Biocare Pharmaceutica is the first national company to launch Azithromycin in injectable formulation in Pakistan. Currently Biocare Pharmaceutica is both brand and market leader in Zithrax (Azithromycin) IV.
Zithrax is indicated for the treatment of atypical pneumonia, Community acquired pneumonia, AECB, PID, STD and for typhoid fever (where intravenous Azithromycin is required).
Standard Dosage in Various Indications:
The recommended dosage regimen for Zithrax (Azithromycin) IV is 500 mg once daily.
Community Acquired Pneumonia (CAP):
Zithrax 500 mg as a single daily dose for at least 2 days followed by oral azithromycin as single daily dose of 500 mg for 7 to 10 days.
Pelvic Inflammatory Disease (PID):
Zithrax 500 mg as a single daily dose for 1 or 2 days followed by oral azithromycin as single daily dose of 250 mg for 7 days
Typhoid Fever (Off-Label):
Australian guidelines recommend Azithromycin 1 g (child: 20 mg/kg up to 1 g) orally or intravenous (IV) until oral Azithromycin can be tolerated, daily for 10 days.
Zithrax (Azithromycin) IV is available as Lyophilized powder for IV infusion in 500 mg Vials.